🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

18 results for “Aura” Clear

  1. 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  2. Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  3. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  4. Bel-sar

    Aura Biosciences

    Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  5. Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  6. TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  7. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  8. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  9. VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  10. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  11. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  12. Dronabinol MDI

    Nektar Therapeutics UK Limited

    Migraine With Aura

    phase 2 small molecule completed

    1 trial

  13. Light-activated AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  14. auranofin

    Ultragenyx UK Limited

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  15. A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Migraine with or without aura

    phase 1 other active

    1 trial

  16. AU-011

    Aura Biosciences

    Non-muscle-invasive Bladder Cancer

    phase 1 small molecule active

    1 trial

  17. Placebo for Rimegepant 75 mg, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    migraine headaches with or without aura

    approved small molecule active

    1 trial

  18. VYDURA 75 mg oral lyophilisate, Placebo for Rimegepant 75 mg

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Migraine attacks with or without aura

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources